摘要
目的比较卡培他滨联合奥沙利铂（XELOX方案）与5-氟尿嘧啶＋亚叶酸钙联合奥沙利铂（FOLFOX4方案）在Ⅲ期结直肠癌辅助化疗中的疗效和安全性。方法回顾性分析118例Ⅲ期结直肠癌患者的临床资料，其中76例应用FOLFOX4方案治疗，42例应用XELOX方案治疗，比较两组患者的3年无病生存率（DFS）和不良反应的发生率。结果FOLFOX4组未完成8个周期化疗的患者有28例，XELOX组有8例，差异有统计学意义（P=0．044）。FOLFOX4组患者的3年DFS为72．4％，XELOX组为73．8％，差异无统计学意义（P=0．866）。FOLFOX4组和XELOX组患者各种常见不良反应的总发生率差异并无统计学意义（均P〉0．05），但在3—4度不良反应中，FOLFOX4组患者中性粒细胞减少的发生率高于XELOX组（P〈0．05），而XELOX组患者血小板减少和手足综合征的发生率高于FOLFOX4组（均P〈0．05）。结论XELOX方案与FOLFOX4方案作为Ⅲ期结直肠癌辅助化疗的疗效相同，但XELOX方案的耐受性更好。
Objective To compare the efficacy and toxicity of capecitabine plus oxaliplatin （XELOX） versus 5-fluorouraeil/leucovofin （5-Fu/LV） plus oxaliplatin （ FOLFOX4 ） regimens as adjuvant chemotherapy for stage Ⅲ colorectal cancer. Methods The clinicopathological data of 118 patients with stage Ⅲ colorectal cancer were studied retrospectively. The patients were assigned to receive either FOLFOX4 regimen （ n = 76） or XELOX regimen （ n = 42）. 3-year disease-free survival （DFS） and adverse events as end points were compared between the two groups. Results The number of patients that failed to finish 8 cycles was higher in FOLFOX4 group （28 vs. 8, P = 0.044）. There was no significant difference for 3-year DFS and all grades adverse events between the two groups. However, the FOLFOX4 group showed more grade 3/4 neutropenia （31.6% vs. 14.3% , P = 0.039） and central venous catheter-associated complication （ 11.8% vs. 4.8% , P = 0. 205 ） , while XELOX showed more grade 3/4 thrombocytopenia （19.0% vs. 6.6%, P=0.038） and hand-foot syndrome （11.9% vs. 1.3%, P=0.012）. Conclusion The results of this analysis indicate that XELOX and FOLFOX4 regimens have very similar efficacy as an adjuvant chemotherapy for stage Ⅲ colon cancer, but XELOX may be safer than FOLFOX4.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2010年第2期152-155,共4页
Chinese Journal of Oncology
关键词
结肠肿瘤
抗肿瘤化疗方案
卡培他滨
奥沙利铂
Colonic neoplasms
Antineoplastic chemotherapy protocols
Capecitabine
Oxaliplatin
